BACKGROUND: Glioblastoma (GB) is the most common malignant primary central nervous system tumor in adults. Standard-of-care therapy includes surgical resection, radiotherapy and temozolomide, but nearly all patients experience disease progression. The purpose of this study was to describe 2 cohorts of patients with recurrent GB submitted to second-line treatment with procarbazine/lomustine/vincristine (PCV) or bevacizumab/irinotecan (BI). MATERIAL AND METHODS: Retrospective analysis of GB patients treated in our center with PCV or BI, after progression with temozolomide, between 2004 and 2012. RESULTS: Among 60 patients, 41 were treated with BI and 19 with PCV. According to the Macdonald criteria, the overall response rate in the BI group was 66% (n = 27) while it was 11% (n = 2) in the PCV group. The median progression-free survival was 5 and 3 months in the BI and PCV group, respectively. The median overall survival (OS) since second-line chemotherapy was 9 months in the BI group and 5 months in the PCV group. The latter group had a worse toxicity profile (grade 3-4: 52.6% vs. 22.0%; grade 1-2: 89.5% vs. 68.3%). CONCLUSIONS: The BI cohort had higher response rates, almost twice the OS and a lower degree of toxicity in contrast to the PCV group. The small number of patients and historical cohorts limits these comparisons.
BACKGROUND:Glioblastoma (GB) is the most common malignant primary central nervous system tumor in adults. Standard-of-care therapy includes surgical resection, radiotherapy and temozolomide, but nearly all patients experience disease progression. The purpose of this study was to describe 2 cohorts of patients with recurrent GB submitted to second-line treatment with procarbazine/lomustine/vincristine (PCV) or bevacizumab/irinotecan (BI). MATERIAL AND METHODS: Retrospective analysis of GB patients treated in our center with PCV or BI, after progression with temozolomide, between 2004 and 2012. RESULTS: Among 60 patients, 41 were treated with BI and 19 with PCV. According to the Macdonald criteria, the overall response rate in the BI group was 66% (n = 27) while it was 11% (n = 2) in the PCV group. The median progression-free survival was 5 and 3 months in the BI and PCV group, respectively. The median overall survival (OS) since second-line chemotherapy was 9 months in the BI group and 5 months in the PCV group. The latter group had a worse toxicity profile (grade 3-4: 52.6% vs. 22.0%; grade 1-2: 89.5% vs. 68.3%). CONCLUSIONS: The BI cohort had higher response rates, almost twice the OS and a lower degree of toxicity in contrast to the PCV group. The small number of patients and historical cohorts limits these comparisons.
Authors: Bruno Carvalho; José Manuel Lopes; Roberto Silva; Joana Peixoto; Dina Leitão; Paula Soares; Ana Catarina Fernandes; Paulo Linhares; Rui Vaz; Jorge Lima Journal: Sci Rep Date: 2021-03-16 Impact factor: 4.379
Authors: Omar H Butt; Alice Y Zhou; Jiayi Huang; William A Leidig; Alice E Silberstein; Milan G Chheda; Tanner M Johanns; George Ansstas; Jingxia Liu; Grayson Talcott; Ruth Nakiwala; Joshua S Shimony; Albert H Kim; Eric C Leuthardt; David D Tran; Jian L Campian Journal: Neurooncol Adv Date: 2021-11-15
Authors: Mustafa Khasraw; Michael Weller; David Lorente; Kathryn Kolibaba; Chee Khoon Lee; Craig Gedye; Macarena I de La Fuente; David Vicente; David A Reardon; Hui K Gan; Andrew M Scott; Isabelle Dussault; Christoph Helwig; Laureen S Ojalvo; Carole Gourmelon; Morris Groves Journal: Neurooncol Adv Date: 2021-04-09